"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

In the United States and worldwide, alcohol consumption remains a leading cause of preventable death and disability.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with ...

Sitting for over 10 hours or more a day is significantly linked to future heart failure and cardiovascular death risk, a new ...

Middle-aged adults with long-term fluctuations in blood pressure may face a higher risk for sudden cardiac death than their ...

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

Neurology patient groups have chided the pharma industry for investing too little into treating disorders of the nervous ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new study from Karolinska ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Patients with IBD don’t face an increased risk for major adverse cardiovascular events when taking Janus kinase inhibitors ...